Pharmaceutical Pricing Disparities Exposed: Bayer's Shift Highlights Inequitable Access to Medicines
Original framing: “Europe must pay more for medicines, says Bayer” — Financial Times
The article echoes a long‑standing pattern of pharmaceutical companies leveraging market power to set prices, a practice rooted in colonial-era extractive economies and post‑war patent expansions. Historical parallels to the 1990s ‘patent cliff’ and earlier antitrust battles illustrate how profit motives have repeatedly overridden public health imperatives. These patterns deepen the systemic inequities highlighted today.
The Bayer case illustrates how historical profit motives, cultural market differences, and absent Indigenous and marginalised voices converge to produce stark pharmaceutical inequities.
By applying a trickster lens, the paradox of a health‑focused industry retreating from equitable markets becomes a catalyst for systemic reform. Integrating scientific evidence, future scenario modeling, and inclusive governance can reshape pricing structures, while artistic‑spiritual narratives remind us that medicines are a collective trust, not merely commodities.